Pfizer's Talzenna snags broader prostate cancer nod than AstraZeneca and Merck's rival PARP med

The PARP inhibitor class is welcoming its second FDA approval in prostate cancer in the span of several weeks. The new approval, for Pfizer, is broader than the first but still limited.